Table 2.

MrOS: Characteristics of subjects with normocalcemic hypoparathyroidism vs normal PTH^a

Parameter	Normocalcemic Hypoparathyroidism (n = 26)	Normal PTH (n = 2224)	P Value
Age, y	73.4 ± 6	73.5 ± 6	.95
Height, cm	174.5 ± 7	174.3 ± 7	.69
Weight, kg	85.7 ± 12	83.4 ± 13	.31
BMI, kg/m2	28.2 ± 4	27.4 ± 4	.43
White, %	23 (88.5)	2031 (91.3)	.49
Daily calcium supplementation, mg	632 ± 520	344 ± 440	.02
Daily calcium supplementation >1000 mg, %	14 (53.9)	508 (22.8)	.0006
Daily vitamin D supplementation, IU	264 ± 230	227 ± 200	.36
Serum calcium adjusted for albumin, mg/dL	9.5 ± 0.4	9.3 ± 0.3	.003
Intact PTH, pg/mLb	12.2 ± 2	32.5 ± 11	<.0001
Serum phosphorus, mg/dL	3.5 ± 0.4	3.2 ± 0.4	.0001
25-Hydroxyvitamin D, ng/mL	28.8 ± 8	26.8 ± 9	.21
Procollagen I N-terminal propeptide, ng/mL	29.8 ± 11	38.4 ± 25	.15
C-terminal telopeptide, ng/mL	0.3 ± 0.2	0.4 ± 0.2	.25
Tartrate-resistant acid phosphatase 5b, U/L	3.1 ± 0.9	3.2 ± 1.0	.77
SHBG, nmol/L	50.2 ± 19	49.4 ± 20	.67
Testosterone, ng/mL	395.0 ± 172	406.2 ± 171	.92
Free testosterone, ng/mL	7.5 ± 3	7.9 ± 3	.55
Estrogen, pg/mL	19.9 ± 12	22.5 ± 9	.09
Free estrogen, pg/mL	0.5 ± 0.2	0.5 ± 0.2	.32
Lumbar spine BMD, g/cm2	1.2 ± 0.12	1.2 ± 0.3	.94
Femoral neck BMD, g/cm2	0.8 ± 0.1	0.8 ± 0.1	.51
Single-slice integral BMD, average L1L2, g/mL	0.21 ± 0.03	0.21 ± 0.04	.48
Single-slice trabecular BMD, average L1L2, g/mL	0.11 ± 0.04	0.11 ± 0.04	.89
Femoral neck, integral BMD, g/mL	0.29 ± 0.05	0.29 ± 0.06	.93
Femoral neck, trabecular BMD, g/mL	0.08 ± 0.04	0.07 ± 0.05	.41

^aResults are shown as mean ± SD. Values in bold remain significant with Bonferroni correction.

^bBy definition, PTH was <14 pg/mL in the subjects with normocalcemic hypoparathyroidism.